Date: 2015-10-28
Type of information: Exercise of an option agreement
Compound: LentiVector® platform technology patents
Company: Oxford Biomedica (UK) GSK (UK)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: licensing
Action mechanism: gene therapy. The LentiVector® platform is a gene therapy platform using lentiviral vectors. The platform can be used in many therapeutic areas, but it has specific advantages in neurological and ocular disorders. In addition, as Lentiviral vectors integrate the gene of interest into target cells, they are particularly suited to the efficient genetic modification of dividing cells such as hematopoietic stem cells and T-cells.
Disease:
Details: * On December 18, 2013, Oxford BioMedica, a UK gene-based biopharmaceutical company, has announced that it has signed an option agreement with GSK which grants GSK an option to a non-exclusive licence under Oxford BioMedica’s LentiVector® platform technology patents for the development and commercialisation of up to six product candidates targeting rare orphan diseases. In 2006, Oxford BioMedica previously granted GSK a non-exclusive licence to its LentiVector® platform technology patents for research purposes.
Financial terms: Financial terms were not disclosed.
Latest news: * On October 28, 2015, Oxford BioMedica announced that GSK has exercised an option to obtain a non-exclusive licence for two rare orphan disease indications under Oxford BioMedica's LentiVector® platform technology patents. This follows an agreement signed between GSK and the Group in December 2013.
